BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21822175)

  • 1. On rare and "super-rare" diseases: an insight from the Republic of Macedonia.
    Gucev ZS; Tasic V; Polenakovic M
    Prilozi; 2011; 32(1):7-11. PubMed ID: 21822175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where are we now in the investigation of rare diseases in the Republic of Macedonia?
    Polenakovic M; Gucev Z; Tasic V
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2014; 35(1):85-6. PubMed ID: 24798597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare diseases with renal involvement in the Republic of Macedonia.
    Tasic V; Lozanovski VJ; Danilovski D; Laban N; Pop-Jordanova N; Polenakovic M; Gucev ZS
    Prilozi; 2011; 32(1):55-67. PubMed ID: 21822178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The many faces of rare diseases (RD): meeting report on Rare Disease in South-Eastern Europe, 15-16 November 2013, Skopje, Republic of Macedonia.
    Gucev Z; Tasic V; Polenakovic M
    Pediatr Endocrinol Rev; 2014 Mar; 11(3):337-8. PubMed ID: 24716400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare Renal Disease in Macedonia - An Update.
    Tasic V; Gucev Z; Polenakovic M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):63-69. PubMed ID: 29668475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rare diseases, definitions and epidemiology].
    Donnart A; Viollet V; Roinet-Tournay M
    Soins Pediatr Pueric; 2013; (274):14-6. PubMed ID: 24228328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Documentary research and self-instruction. Critical reading of a medical article. Practice guidelines. Part 1: rare diseases].
    Cordier JF; Aymé S
    Rev Prat; 2004 Apr; 54(7):777-9. PubMed ID: 15253297
    [No Abstract]   [Full Text] [Related]  

  • 8. Preparing for the Future of Rare Diseases.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():641-648. PubMed ID: 29214596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rare diseases in Lebanon: diagnostic difficulties and therapy].
    Mansour H
    Arch Pediatr; 2015 May; 22(5 Suppl 1):1-2. PubMed ID: 26112493
    [No Abstract]   [Full Text] [Related]  

  • 10. [RARE DISEASES DTC: DIAGNOSIS, TREATMENT AND CARE].
    Mendlovic J; Barash H; Yardeni H; Banet-Levi Y; Yonath H; Raas-Rothschild A
    Harefuah; 2016 Apr; 155(4):241-4, 253. PubMed ID: 27323543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare diseases social epidemiology: analysis of inequalities.
    Kole A; Faurisson F
    Adv Exp Med Biol; 2010; 686():223-50. PubMed ID: 20824449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Orphan drugs. Drugs for treatment of rare diseases].
    Hennemann A
    Med Monatsschr Pharm; 2004 Aug; 27(8):256-9. PubMed ID: 15382448
    [No Abstract]   [Full Text] [Related]  

  • 13. Orphan products: hope for people with rare diseases.
    Rados C
    FDA Consum; 2003; 37(6):10-5. PubMed ID: 14986582
    [No Abstract]   [Full Text] [Related]  

  • 14. 4th Rare Disease South Eastern Europe (See) Meeting Skopje, Macedonia (November 14th, 2015).
    Gucev Z; Tasic V; Polenakovic M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(3):151-6. PubMed ID: 27442409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group.
    Richter T; Nestler-Parr S; Babela R; Khan ZM; Tesoro T; Molsen E; Hughes DA;
    Value Health; 2015 Sep; 18(6):906-14. PubMed ID: 26409619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The burden of rare diseases.
    Ferreira CR
    Am J Med Genet A; 2019 Jun; 179(6):885-892. PubMed ID: 30883013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Solidarity(-ies) in Rare Diseases Research.
    Mascalzoni D; Petrini C; Taruscio D; Gainotti S
    Adv Exp Med Biol; 2017; 1031():589-604. PubMed ID: 29214593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Organization for Rare Disorders (NORD): providing advocacy for people with rare disorders.
    Putkowski S
    NASN Sch Nurse; 2010 Jan; 25(1):38-41. PubMed ID: 20440954
    [No Abstract]   [Full Text] [Related]  

  • 20. Access to care in rare liver diseases: New challenges and new opportunities.
    Jones DEJ; Sturm E; Lohse AW
    J Hepatol; 2018 Mar; 68(3):577-585. PubMed ID: 29113911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.